Mesoblast Limited balance sheet MEOBF

Annual Quarterly

As of Jun 30, 2025, Mesoblast Limited had total assets of $784.7 million and total liabilities of $187.2 million. Total assets were up 17.3% from a year earlier. Stockholders' equity was $597.4 million. It held $161.6 million in cash and investments against $182.3 million of total debt, net debt of $20.8 million. The current ratio, current assets divided by current liabilities, was 1.99.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Jun 30, 2025
FY 2024
Jun 30, 2024
FY 2023
Jun 30, 2023
FY 2022
Jun 30, 2022
FY 2021
Jun 30, 2021
FY 2020
Jun 30, 2020
FY 2019
Jun 30, 2019
FY 2018
Jun 30, 2018
Assets
Cash
162
+156.6%
63
-11.7%
71
+18.0%
60
-55.8%
137
+5.8%
129
+156.5%
50
+33.5%
38
Cash and investments
162
+156.6%
63
-11.7%
71
+18.0%
60
-55.8%
137
+5.8%
129
+156.5%
50
+33.5%
38
Receivables
15
-29.0%
21
+199.4%
7
+58.9%
4
-9.1%
5
+207.6%
2
-61.2%
4
-91.9%
50
Inventory
22
—
—
—
—
—
—
—
Total current assets
204
+136.3%
86
+5.9%
82
+16.9%
70
-52.9%
148
+8.6%
137
+118.4%
63
-38.1%
101
Property and equipment, net
2
+53.9%
1
-18.5%
1
-33.6%
2
-32.3%
3
+31.7%
2
+177.6%
1
-23.8%
1
Total assets
785
+17.3%
669
-0.0%
669
+1.1%
662
-11.1%
745
+1.5%
734
+12.5%
652
-5.8%
692
Liabilities and equity
Accounts payable
19
+169.9%
7
-64.9%
20
-12.7%
23
+17.8%
20
-21.5%
25
+91.2%
13
-31.0%
19
Total current liabilities
103
+40.1%
73
+74.5%
42
-18.3%
51
-45.5%
94
+4.6%
90
+103.3%
44
+84.7%
24
Total liabilities
187
-0.8%
189
+12.7%
168
+1.5%
165
+1.1%
163
-11.4%
184
+7.7%
171
+16.8%
146
Stockholders' equity
597
+24.4%
480
-4.3%
502
+1.0%
497
-14.5%
581
+5.8%
549
+14.2%
481
-11.9%
546
Debt
Debt due within a year
108
+290.7%
28
+132.9%
12
—
106
+63.9%
65
+131.7%
28
—
Long-term debt
68
-32.6%
100
-2.3%
103
+12.2%
92
+123.2%
41
-28.0%
57
-15.2%
67
+13.3%
59
Lease liabilities
6
+36.8%
5
-40.8%
8
-24.7%
10
-8.7%
11
+14.4%
10
—
—
Total debt
182
+37.3%
133
+8.4%
122
+700.9%
15
-90.4%
159
+20.4%
132
+38.3%
95
59
Net cash
-21
+70.3%
-70
-36.6%
-51
-213.2%
45
+307.0%
-22
-793.7%
-2
+94.6%
-45
-218.8%
-22
Ratios
Current ratio
1.99x
1.18x
1.95x
1.36x
1.57x
1.51x
1.41x
4.21x
Debt to equity
0.31x
0.28x
0.24x
0.03x
0.27x
0.24x
0.20x
0.11x
Return on equity
-17.10%
-18.31%
-16.32%
-18.38%
-17.00%
-14.19%
-18.67%
-6.46%
Return on assets
-13.02%
-13.14%
-12.23%
-13.80%
-13.27%
-10.62%
-13.77%
-5.10%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MESO (Nasdaq), MEOBF (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Melbourne, Victoria, Australia
SEC filer status
Large accelerated filer
SEC CIK
1345099

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.